MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations-Reference-Cited by-同舟云学术

MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations

Published:2016-02-03 Issue:324 Volume:8 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Arena Sabrina¹²³,Siravegna Giulia¹³,Mussolin Benedetta¹,Kearns Jeffrey D.⁴,Wolf Beni B.⁴,Misale Sandra¹,Lazzari Luca¹³,Bertotti Andrea¹³,Trusolino Livio¹³,Adjei Alex A.⁵,Montagut Clara⁶⁷,Di Nicolantonio Federica¹³,Nering Rachel⁴,Bardelli Alberto¹³

Affiliation:

1. Candiolo Cancer Institute–Fondazione del Piemonte per l'Oncologia (FPO), IRCCS, Candiolo, Torino 10060, Italy.

2. FIRC Institute of Molecular Oncology (IFOM), Milano 20139, Italy.

3. Department of Oncology, University of Torino, Candiolo, Torino 10060, Italy.

4. Merrimack Pharmaceuticals Inc., Cambridge, MA 02139, USA.

5. Roswell Park Cancer Institute, Buffalo, NY 14263, USA.

6. Medical Oncology Department, Hospital del Mar, Barcelona 08003, Spain.

7. Cancer Research Program, FIMIM (Hospital del Mar Medical Research Institute), Hospital del Mar, Barcelona 08003, Spain.

Abstract

An oligoclonal antibody overcomes drug resistance in colorectal cancers with EGFR mutations.

Funder

European Community's Seventh Framework Programme